Using high-performance liquid chromatography–tandem mass spectrometry, we assessed
trough imatinib plasma levels in 68 patients with chronic myeloid leukemia (CML) who …

BACKGROUND: Imatinib, a competitive inhibitor of BCR–ABL tyrosine kinase, is now the
first-line treatment for chronic myelogenous leukemia (CML). Therapeutic drug monitoring …

Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic
phase. We here describe the correlation of imatinib trough plasma concentrations (Cmins) …

Imatinib is the current standard of care in the treatment of chronic myeloid leukemia (CML),
inducing durable responses and prolonged progression-free survival. However, plasma …

Despite the outstanding results generally obtained with imatinib mesylate (IM) in the
treatment of chronic myeloid leukemia (CML), some patients show a poor molecular …

Cytogenetic and molecular responses to standard-dose imatinib (IM) were correlated with
trough IM plasma levels for 78 patients with chronic myeloid leukemia (CML) after a …

Background This study evaluates the correlation between imatinib trough plasma
concentrations (C min) and clinical response and safety in patients with newly diagnosed …

Purpose This study assessed whether a cycle of “routine” therapeutic drug monitoring (TDM)
for imatinib dosage individualization, targeting an imatinib trough plasma concentration (C …

Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …

Aims This study was designed to investigate the biochemical and physiological covariates or
comedications that affect the pharmacokinetics of imatinib mesylate in patients with chronic …